Rapid development of hypertension by sorafenib: toxicity or target?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 19789317.
- Also identified by DOI 10.1158/1078-0432.CCR-09-1717 and PMC identifier 2762358.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Blood pressure elevation is likely a pharmacodynamic marker of VEGF signaling pathway (VSP) inhibition and could be useful for optimizing safe and effective VSP inhibitor dosing. Blood pressure rises on the first day of treatment, facilitating design and interpretation of future trials aiming to correlate blood pressure changes with clinical outcomes.
Medical subject headings
- Benzenesulfonates
- Hypertension
- Pyridines